CME-Certified Program “On the Cusp of Change: Modernizing the Treatment of Desmoid Tumors With Novel Gamma Secretase Inhibitors".
On behalf of the The Desmoid Tumor Research Foundation and PVI, PeerView Institute for Medical Education, we are very pleased to announce the launch of the CME-certified PeerView onDemand activity, “On the Cusp of Change: Modernizing the Treatment of Desmoid Tumors With Novel Gamma Secretase Inhibitors”
The management of patients with desmoid tumors is currently transitioning from surgical approaches to more conservative strategies by utilizing systemic therapy. The discovery that desmoid tumors are almost universally associated with genetic alterations in the Wnt/β-catenin pathway has provided rationale for the development of gamma secretase inhibitors (GSIs), a new promising class of agents, and several are in late-phase testing. Although no systemic therapies have received regulatory approval for the treatment of desmoid tumors to date, it is important to be prepared to learn how to integrate GSIs into practice.
This PeerView educational activity, based on a recent live symposium, features a panel of leading experts in managing patients with desmoid tumors. The faculty provide expert insights and practical guidance for navigating the latest treatment advances, including GSIs, for desmoid tumors. In addition, illustrative cases and clinical scenarios are discussed to demonstrate the emerging role and integration of novel GSIs in real-world patient care settings.
You may access the online/mobile version of the activity by visiting:
This learner-interactive PeerView program is chaired and presented by Bernd Kasper, MD, PhD from the Mannheim Cancer Center (MCC) in Mannheim, Germany. Dr. Kasper is joined on the faculty by Mrinal Gounder, MD from the Memorial Sloan Kettering Cancer Center in New York, New York and Alessandro Gronchi, MD from the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy.
Upon completion of this activity, participants should be better able to:
- Describe the epidemiology, predisposing factors, molecular pathogenesis, and clinical characteristics of adult and pediatric desmoid tumors
- Implement validated strategies that harness multidisciplinary team-based approaches to diagnose desmoid tumors, including referring patients to sarcoma specialists
- Integrate novel therapeutic approaches based on current evidence to include emerging therapies in the context of clinical trial enrollment into the treatment plans of patients with desmoid tumors
To ensure the greatest potential impact on patient outcomes, we will announce this activity’s availability to medical oncologists, surgical oncologists, general surgeons, advanced practice clinicians, and other healthcare professionals involved in the care of patients with desmoid tumors.
Congruent with adult learning principles, all invitations are created in various concise formats and media. Communications are sent via multiple channels, including email and professional social media, with special emphasis on invitation formats optimized for mobile devices. By using a staggered roll-out schedule, we will maximize the total educational reach by allowing each professional to access the information in his/her preferred format, at a time and place that is conducive to and convenient for their learning.
The presentation can also be downloaded in MP3 format, and the entire program is available as a podcast via the PeerView channels on Apple Podcasts, Spotify, TuneIn, Google Podcasts, and Amazon Alexa. The podcasts and online media player are fully compatible with all mobile devices. Furthermore, all the slides are easily downloadable as a PowerPoint slide kit.
PeerView Practice Aids (below) were also developed as part of this activity. Practice Aids are intended to provide learners with practical patient management tools and references to reinforce the education received in the activity.
Please note that the CTOS 2022 Live Hybrid Symposium was held on November 29, 2022, with the replay immediately following. This on-demand activity will be available for CME credit through December 29, 2023.
We are grateful for the support of SpringWorks Therapeutics, Inc. in making this important educational activity possible.
